| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453683 | Lung Cancer | 2018 | 9 Pages |
Abstract
ddPCR can be used to quantify HOXA9 promoter methylation in FFPE samples. Alone or combined with BVI in a prognostic classifier, HOXA9 promoter methylation could potentially inform the clinical management of patients with early-stage lung adenocarcinoma.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Delphine Lissa, Teruhide Ishigame, Rintaro Noro, Marguerite J. Tucker, Valery Bliskovsky, Steven Shema, Jessica A. Beck, Elise D. Bowman, Curtis C. Harris, Ana I. Robles,